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ABSTRACT
Background. Advanced gastric cancers often metastasize
to distant organs and the peritoneum, leading to a poor
prognosis. Both invasiveness and resistance to anchorage-
independent cell death (anoikis) are important factors in the
process of metastasis. p600 (600-kDa protein), recently
identiﬁed from a cervical cancer cell line, plays a role in
both anoikis resistance and cell migration. In this study, we
examined whether p600 is involved in the progression of
gastric cancer.
Methods. We used both normal gastric mucosal cells and
cancer cells laser-microdissected from 42 gastric cancers
and their normal counterparts, and compared their p600
mRNA expression levels with quantitative reverse trans-
criptase–polymerase chain reaction. We inhibited p600
expression in two gastric cancer cell lines with siRNA and
examined its effect on the invasiveness and anoikis resis-
tance both in vitro and in vivo.
Results. Expression of p600 mRNA was signiﬁcantly
higher in gastric cancer cells than in normal mucosal cells
(P = 0.027). The invasion assay revealed that invasiveness
was signiﬁcantly reduced by inhibition of p600 (P\0.01).
In vitro experiments revealed that cell viability and colony-
formation capacity under anchorage-independent condi-
tions were signiﬁcantly reduced by inhibition of p600
(P\0.05). In vivo experiments also showed that the
establishment of intraperitoneal disseminated tumors was
signiﬁcantly suppressed by transient inhibition of p600
(P\0.001).
Conclusions. Our results strongly suggest that p600 is
involved in gastric cancer progression, and has a potential
to be a new molecular target for gastric cancer therapy.
Gastric cancer is the fourth most common malignancy,
and the second most common cause of cancer mortality
worldwide.
1 Although the proportion of early gastric can-
cers is increasing around the world, many patients still
present with advanced-stage disease.
2 The median survival
of patients with metastatic or unresectable advanced gastric
cancer ranges from 6 to 9 months.
3,4 The control of
advanced gastric cancer remains difﬁcult, despite advances
in chemotherapy and radiotherapy.
5,6 Therefore, new
therapies are needed to improve the 5-year survival rate of
patients with advanced gastric cancer.
Metastasis is a complex process.
7 Gastric cancer cells
need to migrate to and invade through the basement
membrane, and enter the abdominal cavity or the circula-
tory/lymphatic systems. They need to survive without
contacting the extracellular matrix (ECM), invade either
the peritoneum or circulatory/lymphatic systems, and then
proliferate in a foreign environment.
8 Normal epithelial
cells undergo apoptosis after losing contact with neigh-
boring cells or the ECM. This process is termed anoikis.
9
Gastric cancer cells have gained mechanisms to resist
anoikis, and thereby survive and travel through the
abdominal cavity or the lymphatic/circulatory systems,
without the need for ECM contact.
8 Therefore, invasive-
ness and resistance to anoikis are critical for the systemic
spread of cancer cells. Despite the importance of
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cancer, the molecular mechanisms that underlie this pro-
cess have yet to be fully identiﬁed.
Recently, p600 (600-kDa protein) was isolated from
cervical carcinoma cells as a retinoblastoma binding pro-
tein.
10,11 p600 is localized in both the nuclear and the
cytoplasmic compartments.
11 In the nucleus, p600 localizes
to the nuclear matrix components and interacts with reti-
noblastoma binding protein.
11 In the cytoplasm, p600
accumulates at the leading edge of the cell membrane, and
plays an essential role in membrane morphogenesis, which
is crucial for cell migration.
11 p600 has also been shown to
play a critical role in anchorage-independent growth by
binding to viral oncoproteins such as human papillomavirus
16 E7 (HPV-16 E7) and bovine papillomavirus 1 E7
(BPV-1E7).
10,12,13Inhibitionofp600expressionsuppresses
anchorage-independent growth of HPV-16-positive Caski
cervical cancer cells, HPV-16 E7–expressing NIH 3T3
ﬁbroblasts,andBPV-1E6–andE7–expressingC127murine
cells.
10,12,13 Furthermore, anchorage-independent cell
growth was suppressed by inhibition of p600 expression in
U2OS human osteosarcoma cells and NIH 3T3 ﬁbroblasts,
which do not contain viral oncogene sequences, without
affecting their growth in monolayer culture.
10 Several
reports also showed that p600 was upregulated after trans-
formation of mouse embryonic ﬁbroblasts, and upregulated
in a metastatic tumor cell line in a xenogeneic breast cancer
model.
14,15 Therefore, there is a possibility that p600 cor-
relates with metastatic potential in other solid tumors.
In this study, we examined whether p600 expression was
higher in gastric cancer cells than in normal gastric
mucosal cells, and investigated the effect of p600 inhibi-
tion on the invasiveness and anchorage-independent
growth of gastric cancer cells in vitro. Finally, we exam-
ined whether inhibition of p600 prevented the
establishment of disseminated gastric tumors in vivo. Our
results suggest that p600 is involved in gastric cancer
progression and has the potential to be a new molecular
target for gastric cancer therapy.
MATERIALS AND METHODS
Clinical Samples
Forty-two patients with gastric cancer underwent sur-
gical resection at our institute. Experienced pathologists
performed histological examination of all samples,
including tissues from organs adjacent to the gastric
specimens. The study was approved by the ethics com-
mittee of Kyushu University and conducted according to
the Ethical Guidelines for Human Genome/Gene Research
enacted by the Japanese government.
Laser Microdissection
Frozen tissue samples were cut into 8-lm sections, and
one section was stained with hematoxylin and eosin for
histologic examination. Cancer lesions and normal gastric
mucosal lesions were selectively isolated with a laser
microdissection and pressure catapulting system (PALM
Microlaser Technologies, Bernried, Germany) in accor-
dance with the manufacturer’s protocols. After microdis-
section, total RNA was extracted from the selected cells
and subjected to quantitative real-time reverse transcrip-
tase–polymerase chain reaction (qRT-PCR) to measure
p600 mRNA levels as previously described.
16,17
Quantitative Real-Time Reverse Transcriptase–
Polymerase Chain Reaction
We designed speciﬁc primers as follows: p600, 50-CAC
ACATCCTCCACCAAGTG-30 (forward) and 50-GGGCC
CGAAGTAGTGTGATA-30 (reverse); 18S rRNA, 50-GT
AACCCGTTGAACCCCATT-30 (forward) and 50-CCATC
CAATCGGTAGTAGCG-30 (reverse). One-step qRT-PCR
was performed with a QuantiTect SYBR Green RT-PCR
kit (Qiagen, Tokyo, Japan) with a Chrom4 Real-Time
PCR Detection System (Bio-Rad Laboratories, Hercules,
CA) as previously described.
18 Each sample was run in
triplicate, and the expression of p600 mRNA was presented
as the ratio between the expression of p600 mRNA and that
of 18S rRNA.
Cells Lines
Human gastric cancer cell lines (MKN45, MKN74,
KATO III) were purchased from the Japanese Collection of
Research Bioresources (Osaka, Japan). AGS, MKN7, and
NCI-N87 were the gift of the Department of Cancer
Therapy and Research Graduate School of Medical Sci-
ences, Kyushu University. Cells were cultured in RPMI
medium supplemented with streptomycin (100 lg/mL),
penicillin (100 U/mL), and 10% fetal bovine serum (FBS)
at 37C in a humidiﬁed 90% air and 10% CO2 atmosphere.
Transfections
Cells were transfected with p600-targeting small inter-
fering RNA (siRNA) (sense, ggaaagaacaucauuguuaTT;
antisense, uaacaaugauguucuuuccTT) (B-Bridge, Mountain
View, CA), or negative control siRNA (B-Bridge), which
was conﬁrmed not to target a speciﬁc array by electro-
poration with a Nucleofector System (Amaxa Biosys-
tems, Koln, Germany) according to the manufacturer’s
instructions.
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Cells or tissues were lysed in Pro-Prep (iNtRON Bio-
technology, Seongnam, Korea). Cell or tissue lysate
proteins (20–50 lg) were fractionated on 4–15% sodium
dodecyl sulfate–polyacrylamide gel electrophoresis gels
(Bio-Rad Laboratories) and transferred to a polyvinylidene
diﬂouride membrane (Millipore, Billerica, MA). The
membrane was incubated overnight at 4C with anti-p600
(ab86738; Abcam, Cambridge, UK; 1:2500), anti–matrix
metalloproteinase (MMP)-2 (sc-10736; Santa Cruz Bio-
technology, Santa Cruz, CA; 1:200), anti-MMP-7 (sc-
80205; 1:200), anti-MMP-9 (EP1254; Millipore; 1:1000),
anti-urokinase-type plasminogen activator (uPA) (sc-6830;
1:200), anti-E-cadherin (#4065; Cell Signaling Technol-
ogy, Boston, MA; 1:1000) or anti-b-actin (sc-1616;
1:2000) antibodies and then probed with secondary anti-
bodies conjugated to horseradish peroxidase (Santa Cruz
Biotechnology). Immunoblots were detected by enhanced
chemiluminescence with ChemiDoc XRS (Bio-Rad
Laboratories).
In Vitro Invasion Assay
Invasiveness of cancer cells was evaluated by counting
the number of cells invading through a Matrigel-coated
transwell as previously described.
19 Brieﬂy, transwell
inserts with 8-lm pores were coated with Matrigel (20 lg/
well; BD, Bedford, MA), and 1 9 10
5 cells were seeded
into the Matrigel-coated transwell insert. After 48 h of
incubation, cells that had invaded to the lower surface of
the Matrigel-coated membrane were counted under a light
microscope. Each experiment was carried out in triplicate
wells, and independent experiments were repeated at least
three times.
Cell Proliferation Assay
Cells (1 9 10
4/well) were seeded in 24-well tissue
culture plates (Becton Dickinson Labware, Bedford, MA)
and incubated. The number of cells was investigated at the
indicated time points by measuring the ﬂuorescence
intensity of propidium iodide as previously described.
20 All
experiments were performed in triplicate wells and were
repeated at least three times.
Apoptosis Assay and Anoikis Assay
Cells (1 9 10
4/well) were suspended in 24-well tissue
culture plates (Becton Dickinson Labware) for the apop-
tosis assay. For the anoikis assay, cells were suspended
(2 9 10
4/well) in 24-well ultra-low-attachment plates, the
surfaces of which consist of a covalently bound hydrogel
layer that is hydrophilic and electrically neutral (Corning,
Corning, NY). After incubation for 3 days, cells (1 9 10
6)
were pooled and stained with Annexin V-FITC (MACS,
Miltenyi Biotec) followed by propidium iodide. Labeled
cells were analyzed with an Epics Altra ﬂow cytometer
(Beckman Coulter).
Colony-Formation Assay Under Anchorage-Dependent
Conditions
Cells (1 9 10
3/dish) were suspended and incubated.
After 14 days, the number of colonies was counted with a
ChemiDoc XRS System (Bio-Rad Laboratories). All
experiments were performed in triplicate wells and were
repeated at least three times.
Floating Culture and Evaluation of Cell Viability
Cells (2 9 10
4/well) were seeded in 24-well ultra-low-
attachment plates (Corning) and incubated. The number of
cells was investigated at the indicated time points by
measuring the ﬂuorescence intensity of propidium iodide
as previously described.
20 All experiments were performed
in triplicate wells and were repeated at least three times.
Soft Agar Colony-Formation Assay
Cells (1 9 10
3/well in a 6-well plate) were suspended
in RPMI 1640 (1 mL, supplemented with 20% FBS and
0.33% agar) and plated over a layer of solidiﬁed RPMI
1640 medium (1.5 mL, supplemented with 20% FBS and
0.66% agar). After incubation for 28 days, the number of
colonies was counted with a ChemiDoc XRS System
(Bio-Rad Laboratories). All experiments were performed
in triplicate wells and were repeated at least three
times.
In Vivo Studies
MKN45 cells (5 9 10
5) transfected with p600-targeting
siRNA or with control siRNA were injected into the
abdominal cavity of the 25-week-old female SCID mice
(C.B-17/IcrCrj-scid; Kyudo, Tosu, Japan) along with
100 lL of RPMI containing 10% FBS. After 4 weeks,
mice were humanely killed, and any disseminated nodules
of[1 mm in diameter were resected and counted.
Statistical Analysis
Statistical analysis was performed by JMP7 for
Windows software. All data are expressed as mean ±
standard deviation. Differences between groups were
p600 and Gastric Cancer Progression 2059estimated by Student’s t-test and/or Spearman’s rank cor-
relation, and repeated measures were assessed by analysis
of variance. Differences were considered signiﬁcant at
P\0.05.
RESULTS
Gastric Cancer Cells Express High Levels of p600
mRNA
We examined the expression level of p600 mRNA and
protein using bulk tissues from ﬁve patients with gastric
cancer. The expression level of p600 protein was consistent
with the expression level of p600 mRNA, and there was a
tendency forgastric cancer tissues tohave higherexpression
of p600 mRNA and protein than normal gastric tissues
(Fig. 1a). To examine whether p600 mRNA expression was
higher in gastric cancer cells than in normal gastric mucosal
cells, we measured p600 mRNA expression in both laser-
microdissected gastric cancer cells and normal gastric
mucosal cells. p600 mRNA was signiﬁcantly upregulated in
gastric cancer cells compared with normal gastric mucosal
cells (Fig. 1b; P = 0.027). We also investigated the
expression of p600 in a panel of gastric cancer cell lines. For
comparison, we used normal gastric mucosal cells obtained
from surgically resected normal gastric mucosa. We found
thatallgastriccancercelllinesshowedhigherlevelsofp600
expression than normal mucosal cells (Fig. 1c).
Effect of p600 Inhibition on the Invasiveness of Gastric
Cancer Cells
p600 knockdown affects cell membrane rufﬂe forma-
tion, which is linked to cell mobility.
11 We examined the
effect of p600 inhibition on the invasiveness of gastric
cancer cells. To inhibit the expression of p600, we used
p600-targeting siRNA, and we found that p600 expression
was signiﬁcantly inhibited for 5 days after transfection
with p600-targeting siRNA (Fig. 2a, b). The number of
invading MKN45 and AGS cells was signiﬁcantly
decreased by p600 knockdown (Fig. 2c, d; MKN45,
P=0.004; AGS, P\0.001).
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FIG. 1 Gastric cancer cells express high levels of p600 mRNA.
a Expression levels of p600 mRNA and protein in gastric cancer
tissues and normal gastric tissues. (i) Reverse transcriptase–polymer-
ase chain reaction (RT-PCR). (ii) Western blot test. b-Actin was used
as the internal control for immunoblotting. The expression level of
p600 protein was consistent with the expression level of p600 mRNA,
and there was a tendency for gastric cancer tissues to have higher
expression of p600 than normal gastric tissues. b Expression levels of
p600 mRNA in laser-microdissected gastric cancer cells and normal
gastric mucosal cells was determined by quantitative RT-PCR
(n = 42). Gastric cancer cells showed signiﬁcantly higher expression
levels of p600 mRNA than normal gastric mucosal cells (P = 0.027).
c Expression levels of p600 mRNA and protein in gastric cancer cell
lines and normal gastric mucosal cells obtained from surgically
resected normal gastric mucosa. (i) RT-PCR. (ii) Western blot test.
b-Actin was used as the internal control for immunoblotting. Gastric
cancer cell lines showed higher levels of p600 expression than normal
gastric mucosal cells
c
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FIG. 2 Inhibition of p600 reduces the invasiveness of gastric cancer
cells. a Effect of p600-targeting siRNA in the MKN45 gastric cancer
cell line. (i) Reverse transcriptase–polymerase chain reaction (RT-
PCR). (ii) Western blot test. b Effect of p600-targeting siRNA in the
AGSgastriccancercellline.(i)RT-PCR.(ii)Westernblottest.b-Actin
wasusedastheinternalcontrolforimmunoblotting.p600expressionin
bothgastriccancercelllineswasinhibitedbyp600-targetingsiRNAfor
at least 5 days. c (i) Microscopic appearance of the invading control
siRNA-transfected MKN45 cells, and (ii) p600-targeting siRNA-
transfected MKN45 cells. (iii) Number of invaded cells. d (i) Micro-
scopic appearance of invading control siRNA-transfected AGS cells,
and (ii) p600-targeting siRNA-transfected AGS cells. (iii) Number of
invaded cells. Data are expressed as mean ± SD. Inhibition of p600
reduced the invasiveness of both gastric cancer cell lines (MKN45,
P = 0.004; AGS, P\0.001). e Western blot analysis of urokinase-
type plasminogen activator (uPA), matrix metalloproteinase (MMP)-2,
MMP-7, and MMP-9 expression levels. (i) MKN45. (ii) AGS. b-Actin
wasusedastheinternalcontrolforimmunoblotting.MMP-7expression
was decreased by inhibition of p600 in both gastric cancer cell lines.
f Western blot analysis of E-cadherin expression in MKN45 gastric
cancer cells. b-Actin was used as the internal control for immunoblot-
ting. Expression of E-cadherin was higher in p600-targeting siRNA-
transfected MKN45 cells than in control siRNA-transfected MKN45
cells
p600 and Gastric Cancer Progression 2061Some reports show that MMP-2, MMP-7, MMP-9, and
uPA affect gastric cancer invasion.
21–24 Therefore, we
examined the expression of these three MMPs and uPA.
Although we observed no difference in the expression
levels of MMP-2, MMP-9, and uPA between p600-target-
ing siRNA-transfected cells and control siRNA-transfected
cells, the expression level of MMP-7 was decreased by
inhibition of p600 in both gastric cancer cell lines (MKN45
and AGS; Fig. 2e). A previous report shows that the
expression of E-cadherin is decreased by MMP-7.
25
Therefore, we also examined the expression of E-cadherin.
The results showed that E-cadherin was overexpressed in
MKN45 cells by inhibition of p600 (Fig. 2f).
Effect of p600 Inhibition on Anchorage-Dependent Cell
Proliferation, Apoptosis, and Colony-Formation
Capacity of Gastric Cancer Cells
p600 did not affect the growth of U2OS human osteo-
sarcoma cells in monolayer culture.
10 Therefore, we
examined the effect of p600 inhibition on anchorage-
dependent cell proliferation, apoptosis rate, and colony-
formation capacity of gastric cancer cells in monolayer
culture. Inhibition of p600 did not affect cell proliferation,
apoptosis rate, or colony-formation capacity of MKN45
gastric cancer cells (Fig. 3a–c). Similar results were
obtained with AGS gastric cancer cells (data not shown).
Inhibition of p600 Sensitizes Gastric Cancer Cells
to Anoikis and Decreases Cell Viability and Colony-
Formation Capacity Under Anchorage-Independent
Conditions
We examined the effect of p600 inhibition on anchor-
age-independent cell viability and sensitivity to anoikis in
gastric cancer cells. Inhibition of p600 signiﬁcantly
reduced cell viability (Fig. 4a; MKN45, P = 0.033; AGS,
P\0.001) and sensitized both MKN45 and AGS cells to
anoikis (Fig. 4b, c). Furthermore, we investigated the
effects of p600 inhibition on the anchorage-independent
colony-formation capacity of MKN45 and AGS cells, and
we found that the colony-formation capacity of cells
transfected with p600-targeting siRNA was signiﬁcantly
reduced compared with that of cells transfected with con-
trol siRNA under anchorage-independent conditions
(Fig. 4d, e; MKN45, P\0.001; AGS, P = 0.003).
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FIG. 3 Inhibition of p600 does not affect cell proliferation, apop-
tosis, and colony-formation capacity under anchorage-dependent
conditions. a Proliferation assay under anchorage-dependent condi-
tions. There was no signiﬁcant difference between p600-targeting
siRNA-transfected MKN45 cells and control siRNA-transfected
MKN45 cells in terms of cell proliferation under anchorage-depen-
dent conditions. b Proportion of apoptotic cells in (i) control siRNA-
transfected MKN45 cells and (ii) p600-targeting siRNA-transfected
MKN45 cells as analyzed by ﬂow cytometry. There was no signiﬁcant
difference between p600-targeting siRNA-transfected MKN45 cells
and control siRNA-transfected MKN45 cells in terms of apoptotic
cells proportion. c Macroscopic appearance of colonies formed under
anchorage-dependent conditions; (i) control siRNA-transfected
MKN45 cells and (ii) p600-targeting siRNA-transfected MKN45
cells. (iii) Data graph. Data are expressed as mean ± SD. There was
no signiﬁcant difference between p600-targeting siRNA-transfected
MKN45 cells and control siRNA-transfected MKN45 cells in terms of
colony-formation capacity under anchorage-dependent conditions
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of Intraperitoneal Disseminated Tumors In Vivo
Finally, we examined whether the inhibition of p600
suppressed the establishment of intraperitoneal dissemi-
nated tumors after intraperitoneal injection of MKN45
gastric cancer cells in vivo. Although both p600-targeting
siRNA-transfected cells and control siRNA-transfected
cells developed disseminated nodules within the abdominal
cavity, the number of nodules was signiﬁcantly decreased
by inhibition of p600 (Fig. 5; P\0.001). There was no
statistically signiﬁcant difference in the size of the dis-
seminated nodules between mice injected with p600-
targeing siRNA-transfected cells and those injected with
control siRNA-transfected cells (data not shown). These
results suggest that p600 is involved in the establishment of
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FIG. 4 Inhibition of p600 sensitizes gastric cancer cells to anoikis
and reduces their viability under anchorage-independent conditions.
a Cell viability assay under anchorage-independent conditions. The
viability of (i) MKN45 and (ii) AGS gastric cancer cells were reduced
by inhibition of p600 (MKN45, P = 0.033; AGS, P\0.001).
b Proportion of apoptotic (anoikis) cells under anchorage-independent
conditions in (i) control siRNA-transfected MKN45 cells and (ii)
p600-targeting siRNA-transfected MKN45 cells as analyzed by ﬂow
cytometry. c Proportion of apoptotic (anoikis) cells in (i) control
siRNA-transfected AGS cells and (ii) p600-targeting siRNA-trans-
fected AGS cells as analyzed by ﬂow cytometry. d Macroscopic
appearance of colonies formed in soft agar; (i) control siRNA-
transfected MKN45 cells and (ii) p600-targeting siRNA-transfected
MKN45 cells. (iii) Number of colonies. e Macroscopic appearance of
colonies formed in soft agar; (i) control siRNA-transfected AGS cells
and (ii) p600-targeting siRNA-transfected AGS cells. (iii) Data graph.
Data are expressed as mean ± SD. The number of colonies was
reduced by inhibition of p600 (MKN45, P\0.001; AGS, P = 0.003)
p600 and Gastric Cancer Progression 2063intraperitoneal disseminated gastric tumors, but not in
anchorage-dependent cell growth in vivo.
DISCUSSION
In this study, we found that p600 expression was higher
in gastric cancer cells than in normal gastric mucosal cells.
Also, our in vitro experiments showed that both the inva-
siveness and anoikis resistance of gastric cancer cells were
decreased by inhibition of p600. Furthermore, our in vivo
experiments showed that the establishment of intraperito-
neal disseminated gastric tumors was suppressed by
inhibition of p600.
As far as we know, there are no reports investigating the
differences of p600 expression levels between cancer cells
and normal cells in clinical samples. Therefore, we inves-
tigated the expression of p600 mRNA in gastric cancer
cells and compared it with that in normal gastric mucosal
cells. As the result, p600 mRNA was statistically signiﬁ-
cantly upregulated in gastric cancer cells compared with
normal gastric mucosal cells. Out of six gastric cancer cell
lines, the ﬁve cell lines established from metastatic sites
exhibited higher levels of p600 expression than the cell line
established from a primary site. Recent results in a xeno-
geneic breast cancer model showed that the level of p600
expression was higher in metastatic tumors than in primary
tumors.
14 This supports our results, suggesting that p600 is
involved in the progression of gastric cancer.
The ﬁrst step in metastasis involves migration of cancer
cells to, and invasion through, the basement membrane.
8 In
our study, inhibition of p600 decreased the number of
invaded cells and the expression level of MMP-7 in both
gastric cancer cell lines (MKN45 and AGS). Furthermore,
inhibition of p600 induced overexpression of E-cadherin in
MKN45 cells. A previous study reported that MMP-7
induced an epithelial–mesenchymal transition-like process
in tumor cells by causing the shedding E-cadherin pro-
tein.
26 Although further study of the relationship between
p600, MMP-7, and E-cadherin is needed, it is possible that
inhibition of p600 reduces invasiveness though the inhi-
bition of epithelial–mesenchymal transition-like processes.
Once they have migrated through the basement mem-
brane, gastric cancer cells in the abdominal cavity and/or
the circulatory and lymphatic systems have to remain
viable without contacting the ECM. They then have to
implant at a distant site and initiate tumor growth.
8 Our
data showed that gastric cancer cells were sensitized to
anoikis and that their colony-formation capacity was sup-
pressed under anchorage-independent conditions by
inhibition of p600. Previous studies have shown that acti-
vation of focal adhesion kinase plays a central role in
anoikis, and that its activation is inhibited by the inhibition
of p600.
11,27,28 Therefore, p600 may be an important reg-
ulator of anoikis resistance in gastric cancer, although
further studies are required to investigate this mechanism.
For the in vivo experiments, we injected gastric cancer
cells into the peritoneal cavity of SCID mice and found that
the establishment of intraperitoneal disseminated tumors
was statistically signiﬁcantly suppressed by inhibition of
p600. Peritoneal dissemination of gastric cancer cells is a
multistep process comprising invasion into the serosa from
the stomach, detachment from the primary site and
movement into the peritoneal cavity, attachment to the
distant peritoneum, invasion into the subperitoneal space,
and proliferation. Because the process of movement from a
primary site into the peritoneum was not represented,
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FIG. 5 Inhibition of p600
suppresses the establishment of
intraperitoneal disseminated
tumors. a Macroscopic
appearance of the
intraperitoneal disseminated
nodules; (i) control siRNA-
transfected MKN45 cells
injected into SCID mice, and
(ii) p600-targeting siRNA-
transfected MKN45 cells
(n = 10/group). Arrows
indicate intraperitoneal
disseminated nodules. (iii)
Resected disseminated nodules
from SCID mice. b Data graph.
Data are expressed as
mean ± SD. The number of
intraperitoneal disseminated
nodules was signiﬁcantly
reduced by p600 inhibition
(P\0.001)
2064 H. Sakai et al.peritoneal dissemination was not exactly represented by
our in vivo experiment. However, because establishment of
peritoneal dissemination after detachment from the primary
site is one of key processes in peritoneal dissemination of
gastric cancer cells, our data suggest the possibility that
peritoneal dissemination is inhibited by inhibition of p600.
In conclusion, our results show that p600 expression is
higher in gastric cancer cells than in normal gastric
mucosal cells, and that knockdown of p600 inhibits the
invasiveness and anoikis resistance of gastric cancer cells.
This implies that p600 has potential as a new molecular
target of gastric cancer therapy. Gene therapy targeting
p600 might have a major effect on the processes involved
in tumor progression, such as tumor invasion, metastasis,
and dissemination, rather than in initiation and prolifera-
tion of tumors. Therefore, it is expected that the effects of
p600 inhibition on gastric cancer would be best seen when
used in combination with other treatments such as che-
motherapy, although further study of the mechanism
underlying the action and function of p600 is required.
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